FDA's Combo Products Review Transformation Begins
Pilot project sets timelines for lead and consulting centers that will feed into more substantial changes in PDUFA VI.
You may also be interested in...
FDA officials discuss difficulties dealing with complex combination products, the future of the agency's Centers, and promotion of industry collaboration at DIA meeting.
Center for Drug Evaluation and Research's long-time director of oncology/hematology products office will continue as signatory on drug reviews even after new Cancer Moonshot-driven structure takes effect.
House and Senate letters ask why Mylan's autoinjector doesn't have competition, offering a preview of potential debates on renewal of the generic user fee program.